Caesars Entertainment
CZR
$29.49
-0.54%
Caesars Entertainment is a leading US gaming and hospitality operator whose portfolio spans roughly 50 domestic properties, split almost evenly between the Las Vegas market (48% of 2025 EBITDAR) and regional casinos (49%), with a smaller managed and digital segment that produced only marginal EBITDA. The company's brands — Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo — give it one of the broadest footprints in the US casino industry, and it also owns the US portion of the William Hill sports betting platform following the sale of the international operation in 2022. The dominant investor narrative today is the proposed $17.6 billion take-private acquisition by Fertitta Entertainment and its Golden Nugget resorts, announced in late May 2026 at a reported 49% cash premium, which has effectively capped the stock's trading range and shifted the debate from fundamentals to deal-completion risk. That deal news has overshadowed an otherwise challenging operating picture, including a heavy debt load, a still-unprofitable digital transition, and the exit of institutional holder Progeny 3, which flagged concerns about leverage and the digital business.…
CZR
Caesars Entertainment
$29.49
Related headlines
Investment Opinion: Should I buy CZR Today?
The synthesized recommendation is Hold, reflecting the binary nature of the pending take-private deal and the lack of standalone fundamental support. The analyst consensus rating is hold with a recommendation mean of 2.93, and the average target price of $31.27 implies just 5.5% upside from $29.65. The core thesis is that the stock is a deal-arbitrage vehicle rather than a fundamental growth story, with the $17.6 billion Fertitta acquisition at a 49% premium capping upside and providing a soft floor.
Supporting evidence for the Hold rating includes: (1) EV/EBITDA of 9.21x is within the sector's 8x-12x range, suggesting fair enterprise value; (2) revenue growth of 2.96% year-over-year is modest but positive, with Q2 2026 revenue of $2.993 billion; (3) operating margin has been stable at 17.1%-18.0% across five quarters, demonstrating core profitability; (4) trailing-twelve-month free cash flow of $610 million and Q2 2026 FCF of $346 million show improving cash generation; and (5) the PS ratio of 0.42x is near the bottom of its historical band, offering limited downside from a multiple perspective. However, the forward PE of 40.99x on estimated EPS of $0.17 is expensive, and the negative net margin of -4.37% highlights persistent unprofitability.
The biggest risks that could invalidate the Hold thesis are: (1) deal failure, which could send the stock toward its 52-week low of $17.86, a 40% decline; (2) continued earnings deterioration, with trailing EPS of -$0.10 and interest expense of $576 million overwhelming operating income; and (3) institutional exit, as Progeny 3's departure signals concerns about leverage and digital transition. The rating would upgrade to Buy if the deal closes at or above $35.00 or if standalone revenue growth accelerates above 5% with positive net income. It would downgrade to Sell if the deal collapses or if free cash flow turns negative. The stock appears fairly valued relative to its history and peers, with the current price reflecting deal economics rather than standalone fundamentals.
Sign up to view all
CZR 12-Month Price Forecast
The 12-month outlook is dominated by the pending Fertitta take-private deal, which has shifted the investment thesis from fundamentals to deal-completion risk. The base case (55% probability) assumes the deal closes at or near proposed terms, with the stock trading around $30-$33. The bull case (25%) hinges on improved terms or a competing bid, while the bear case (20%) reflects deal failure and a re-rating toward standalone fundamentals. Valuation is fair on an EV/EBITDA basis but rich on forward earnings, and the negative net margin of -4.37% highlights persistent unprofitability. I would upgrade to bullish if the deal closes at a premium above $35 or if standalone revenue growth accelerates above 5% with positive net income. I would downgrade to bearish if the deal collapses or if free cash flow turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Caesars Entertainment's 12-month outlook, with a consensus price target around $31.27 and implied upside of +6.0% versus the current price.
Average Target
$31.27
0 analysts
Implied Upside
+6.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$31 - $35
Analyst target range
Coverage is solid with 15 analysts, but sentiment is decidedly neutral: the consensus recommendation is "hold" with a recommendation mean of 2.93 (where 3.0 is hold), and the average target price of $31.27 implies just 5.5% upside from the current $29.65 price. The distribution skews cautious, and the institutional ratings history shows a clear wave of downgrades through 2026 — TD Cowen moved from Buy to Hold on July 29, Barclays from Overweight to Equal Weight on July 9, Stifel from Buy to Hold on June 15, Deutsche Bank from Buy to Hold on June 1, and CBRE, Truist, and Susquehanna all shifted from Buy/Positive to Hold/Neutral in late May. This pattern of downgrades into the deal announcement suggests analysts are aligning their ratings with the take-private price rather than expressing independent fundamental views, which is typical when a stock trades near a proposed transaction value. The target range is unusually tight — a low of $31.00 and a high of $35.00, a spread of only about 13% — which signals high conviction that the stock will trade in a narrow band around the deal price rather than wide disagreement about fundamentals. The high target of $35.00 implies either a higher competing bid or deal completion at improved terms, while the low target of $31.00 essentially prices in the current deal value with minimal upside. Estimated EPS averages of $0.17 (range of -$0.05 to $0.35) and estimated revenue of $12.21 billion (range of $11.88 billion to $13.09 billion) show analysts expect only marginal profitability and low-single-digit revenue growth, reinforcing that the standalone business does not justify a premium multiple. The tight target spread and the clustering of targets just above the current price indicate the market is in a deal-arbitrage regime, where the stock's fate depends almost entirely on whether the Fertitta transaction closes rather than on operating performance.
Drowning in data?
Find the real signal!
Bulls vs Bears: CZR Investment Factors
The bear case currently has stronger evidence on standalone fundamentals, with negative net income, a 7.52x debt-to-equity ratio, and just 2.96% revenue growth. However, the bull case is anchored by the pending $17.6 billion take-private deal at a 49% premium, which has effectively capped the stock's trading range and shifted the investment debate from operations to deal-completion risk. The single most important tension is whether the Fertitta acquisition closes: if it does, the stock likely trades toward the $31-$35 analyst target range; if it fails, the stock could fall toward its 52-week low of $17.86, a 40% decline. Analyst sentiment is neutral with a consensus hold rating and a recommendation mean of 2.93, reflecting the deal-arbitrage regime. With a beta of 1.751, the stock is 75% more volatile than the S&P 500, amplifying the binary nature of this investment.
Bullish
- Take-Private Deal Caps Downside: Fertitta Entertainment's $17.6 billion take-private offer at a 49% cash premium provides a hard floor near the current price, with the stock trading at $29.65 versus the 52-week high of $30.88. The deal structure limits downside to deal-break risk rather than fundamental deterioration.
- Strong Free Cash Flow Generation: Trailing-twelve-month free cash flow reached $610 million, with $346 million generated in Q2 2026 alone, versus just $18 million in Q1 2025. This improving cash generation supports debt servicing and validates the underlying business's cash-producing ability.
- Stable Operating Margins: Operating margin has held remarkably steady in the 17.1% to 18.0% range across the last five quarters, with Q2 2026 at 17.1%. This consistency demonstrates the core casino business is reliably profitable before financing costs.
- Attractive EV/EBITDA Valuation: EV/EBITDA of 9.21x sits comfortably within the gaming sector's typical 8x-12x range, suggesting the enterprise is reasonably valued relative to peers. The PS ratio of 0.42x is near the bottom of its historical band, offering limited downside from a multiple perspective.
Bearish
- Crushing Debt Burden: Debt-to-equity of 7.52x and a current ratio of just 0.80 highlight severe leverage with limited short-term liquidity. Q2 2026 interest expense of $576 million overwhelmed operating income of $513 million, driving a net loss of $41 million.
- Negative Profitability: Trailing EPS of -$0.10 and a net margin of -4.37% reflect persistent unprofitability despite healthy EBITDA of $875 million (29.2% margin). The gap between operating profitability and net losses is entirely due to financing costs.
- Sluggish Revenue Growth: Q2 2026 revenue of $2.993 billion grew just 2.96% year-over-year, with multi-quarter revenue hovering in a narrow $2.79-$2.99 billion band. This mature, low-growth profile limits operating leverage and organic value creation.
- Rich Forward Valuation: Forward PE of 40.99x on estimated EPS of just $0.17 is expensive for a mature, highly levered casino operator. This multiple is difficult to justify on organic growth under 3% and likely reflects deal premium rather than standalone fundamentals.
CZR Technical Analysis
Caesars is in a slow, low-volatility uptrend that has flattened into a tight consolidation near the top of its range. The stock is up 10.22% over the past year and 25.85% year-to-date, and at $29.65 it sits at roughly 96% of its 52-week range (52-week low of $17.86, high of $30.88), meaning it is trading just below its highs rather than at a discount. That positioning is consistent with a stock that has already re-rated on deal news rather than one showing fresh momentum, and the 34.91% max drawdown over the past year shows how sharply it can move when the narrative shifts. Short-term momentum has actually stalled: the stock is down 0.13% over the past month and down 2.44% over three months, a clear deceleration from the 11.76% six-month gain. This divergence — strong YTD performance but negative 1-month and 3-month returns — suggests the market is treating the stock as a deal vehicle rather than a growth story, with the price pinned near the proposed transaction value and little incentive to chase it higher. Relative strength confirms the lag: CZR trails SPY by 0.72 percentage points over one month, 5.78 points over three months, and 4.79 points over one year, even though it leads by 12.99 points YTD. The key technical levels are the 52-week high of $30.88 as resistance and the 52-week low of $17.86 as distant support, with the current $29.65 price sitting in the upper quartile of that band. A breakout above $30.88 would signal the market expects a higher bid or deal completion on improved terms, while a breakdown below the mid-$20s would suggest deal skepticism is building. With a beta of 1.751, the stock is roughly 75% more volatile than the S&P 500, which argues for smaller position sizes and wider stops, particularly given the binary nature of the pending acquisition.
Beta
1.85
1.85x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$18-$31
Price range past year
Annual Return
+19.6%
Cumulative gain past year
| Period | CZR Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +0.9% |
| 3m | -0.9% | +3.4% |
| 6m | +9.7% | +14.4% |
| 1y | +19.6% | +16.2% |
| ytd | +25.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CZR Fundamental Analysis
Caesars' revenue trajectory is modestly positive but uninspiring, with Q2 2026 revenue of $2.993 billion representing 2.96% year-over-year growth from $2.907 billion in Q2 2025. The multi-quarter trend shows revenue hovering in a narrow band — $2.794 billion in Q1 2025, $2.907 billion in Q2 2025, $2.869 billion in Q3 2025, $2.916 billion in Q4 2025, $2.870 billion in Q1 2026, and $2.993 billion in Q2 2026 — indicating a mature, low-growth business rather than an accelerating one. Segment data shows casino revenue of $1.759 billion as the dominant driver, followed by owned hotel revenue of $495 million and food and beverage at $426 million, a mix that leaves the company heavily exposed to gaming volumes and regional consumer discretionary spending. The lack of meaningful top-line acceleration limits operating leverage and explains why the investment case has shifted toward the take-private deal rather than organic growth. Profitability remains the core fundamental problem: Q2 2026 net income was negative $41 million, with a net margin of -4.37% and trailing EPS of -$0.10, even though operating income was a healthy $513 million (17.1% operating margin) and EBITDA was $875 million (29.2% EBITDA margin). The gap between solid operating profitability and negative net income is driven almost entirely by interest expense of $576 million in the quarter, which overwhelms operating income and reflects the company's enormous debt load. Gross margin has been volatile in reported terms — 100% in Q2 2026 due to cost-of-revenue classification, 50.3% in Q1 2026, and 37.3% in Q4 2025 — but the operating margin has been remarkably stable in the 17.1% to 18.0% range across the last five quarters, suggesting the core casino business is consistently profitable before financing costs. The balance sheet is the central risk: debt-to-equity of 7.52x, a current ratio of just 0.80, and a debt ratio of 0.78 mean the company is highly leveraged with limited short-term liquidity cushion. Free cash flow tells a more encouraging story, with $610 million in trailing-twelve-month FCF and $346 million generated in Q2 2026 alone, versus just $18 million in Q1 2025, showing meaningful improvement in cash generation. However, ROE of -14.33% and ROA of 4.01% highlight that shareholder returns remain negative on a net-income basis, and the company depends on internally generated cash plus refinancing to service its debt rather than on external equity issuance.
Quarterly Revenue
$3.0B
2026-06
Revenue YoY Growth
+3.0%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$610000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CZR Overvalued?
Because Caesars reported negative trailing net income (EPS of -$0.10) and a trailing PE of -9.67x, the PE ratio is not meaningful for valuation; the appropriate primary metric is the price-to-sales ratio of 0.42x, supplemented by EV/EBITDA of 9.21x and EV/Sales of 2.68x. The forward PE of 40.99x is positive only because analysts expect a swing to profitability (estimated average EPS of $0.17), and the enormous gap between the negative trailing PE and the positive forward PE implies the market is pricing in a sharp earnings recovery that has yet to materialize. The forward PE of 41x on barely positive expected EPS is a rich multiple for a mature, highly levered casino operator, which suggests the stock is being valued on deal economics rather than standalone fundamentals. On a peer-comparison basis, the PS ratio of 0.42x and EV/EBITDA of 9.21x look reasonable for the gaming sector, where casino operators typically trade in the 8x-12x EV/EBITDA range, but the PB ratio of 1.39x is above the company's own recent lows and reflects the equity's leveraged sensitivity to enterprise value. The forward PE premium versus a sector that generally trades in the mid-teens to low-20s on earnings is difficult to justify on organic growth of under 3%, and it is better explained by the pending acquisition premium embedded in the share price. Historically, Caesars' PS ratio has compressed dramatically — from 7.72x in Q4 2021 and 3.58x in Q4 2023 to 2.06x in Q2 2026 and 0.42x on the current market-cap-to-revenue basis — placing the stock near the bottom of its own historical valuation band. That compression reflects both the market's reduced growth expectations and the heavy debt burden, but it also means the current multiple offers little downside protection if the deal falls through, since the stock would likely re-rate toward standalone fundamentals rather than stay at deal-supported levels.
PE
-9.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~34x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Caesars faces severe financial and operational risks stemming from its enormous debt load. Debt-to-equity of 7.52x and a current ratio of 0.80 indicate the company is highly leveraged with minimal short-term liquidity cushion. Q2 2026 interest expense of $576 million exceeded operating income of $513 million, producing a net loss of $41 million and a net margin of -4.37%. The digital segment remains unprofitable, and the exit of institutional holder Progeny 3 flagged concerns about both leverage and the digital transition. Revenue concentration in casino operations ($1.759 billion of $2.993 billion in Q2 2026) and regional markets (49% of EBITDAR) leaves the company exposed to gaming volume fluctuations and regional consumer discretionary spending.
Market and competitive risks are amplified by the stock's premium valuation relative to its growth profile. The forward PE of 40.99x on estimated EPS of $0.17 is rich for a mature casino operator with sub-3% revenue growth, and the negative trailing PE of -9.67x makes the stock difficult to value on earnings. With a beta of 1.751, Caesars is roughly 75% more volatile than the S&P 500, meaning market downturns or sector rotation could disproportionately impact the share price. The stock trails SPY by 5.78 percentage points over three months and 4.79 points over one year, despite leading by 12.99 points YTD, suggesting recent relative weakness. Competitive pressures from Penn Entertainment's 48% YTD rally and MGM's buyout speculation could shift investor attention and capital away from Caesars. Regulatory risks around sports betting and casino licensing, plus macro sensitivity to consumer discretionary spending, add further uncertainty.
The worst-case scenario is a failed take-private deal combined with deteriorating fundamentals. If the Fertitta acquisition collapses, the stock could re-rate toward standalone fundamentals, potentially falling to the 52-week low of $17.86, representing a 40% decline from the current $29.65. The 34.91% max drawdown over the past year demonstrates how sharply the stock can move when the narrative shifts. A deal break would likely trigger analyst downgrades and institutional selling, with the stock potentially testing the mid-teens if debt concerns intensify. In this adverse scenario, an investor could lose 40% or more from current levels, with the bear-case analyst target of $31.00 providing little downside protection since it assumes deal completion.
FAQ
The most severe risk is deal failure: if the Fertitta take-private acquisition collapses, the stock could fall toward its 52-week low of $17.86, a 40% decline. Second is the crushing debt burden, with debt-to-equity of 7.52x and interest expense of $576 million in Q2 2026 overwhelming operating income of $513 million. Third is persistent unprofitability, with trailing EPS of -$0.10 and a net margin of -4.37%, despite stable operating margins. Fourth is the digital segment's continued losses and the exit of institutional holder Progeny 3, which flagged concerns about leverage and the digital transition. With a beta of 1.751, the stock is also highly sensitive to market downturns.
The 12-month forecast is dominated by the pending Fertitta take-private deal. The base case (55% probability) assumes the deal closes at or near proposed terms, with the stock trading in the $30-$33 range around the average analyst target of $31.27. The bull case (25%) assumes improved deal terms or a competing bid, driving the stock to $35-$38. The bear case (20%) assumes deal failure, with the stock falling to $17.86-$22.00. The most likely scenario is the base case, with the key assumption being that the acquisition closes without major regulatory or financing hurdles. However, the binary nature of the deal means the stock could move sharply in either direction based on deal news.
CZR appears fairly valued on an enterprise basis but expensive on earnings. The EV/EBITDA of 9.21x is within the gaming sector's typical 8x-12x range, and the PS ratio of 0.42x is near the bottom of its historical band, suggesting the market is not paying a premium for the enterprise. However, the forward PE of 40.99x on estimated EPS of $0.17 is rich for a mature casino operator with sub-3% revenue growth. The negative trailing PE of -9.67x makes earnings-based valuation meaningless. The market appears to be pricing in the take-private deal rather than standalone fundamentals, with the stock trading near the proposed transaction value. If the deal fails, the stock would likely re-rate toward standalone fundamentals, implying significant downside.
From a risk/reward perspective, CZR is a hold rather than a compelling buy at $29.65. The average analyst target of $31.27 implies just 5.5% upside, while the 52-week low of $17.86 represents 40% downside if the Fertitta deal fails. The stock is trading at 96% of its 52-week range, leaving little room for appreciation on standalone fundamentals. However, the pending take-private deal at a 49% premium provides a soft floor and makes this a deal-arbitrage opportunity rather than a fundamental investment. For event-driven investors with high risk tolerance, the risk/reward is balanced; for long-term fundamental investors, the negative net margin of -4.37% and 7.52x debt-to-equity ratio are significant concerns.
CZR is currently suited for short-term, event-driven trading rather than long-term holding. The pending take-private deal creates a binary outcome that will likely resolve within 12 months, making the stock a deal-arbitrage vehicle. The company's negative net margin of -4.37%, 7.52x debt-to-equity ratio, and 2.96% revenue growth make it unattractive as a long-term fundamental investment. The beta of 1.751 indicates high volatility, and the 34.91% max drawdown over the past year shows the potential for sharp declines. A suggested minimum holding period would be until the deal resolution, expected within 6-12 months. Long-term investors should wait for clarity on the deal or a significant improvement in standalone fundamentals before committing capital.
